2015 Fiscal Year Final Research Report
The study of novel chondrosarcoma therapy by PEDF
| Project/Area Number |
24592243
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
Akiyama Toru 自治医科大学, 医学部, 准教授 (40376471)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAITA Kazuo 自治医科大学, 医学部, 非常勤講師 (20241995)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Keywords | 色素上皮由来因子 / 軟骨肉腫 / 破骨細胞 / 抗がん剤 / 骨代謝 / 血管新生阻害因子 |
|---|
| Outline of Final Research Achievements |
Chondrosaroma is a primary malignant bone tumor. Malignant tumor requires angiogenesis induction for its development. Bone tumor requires surrounding bone destruction for their development as well. Osteoclast is the sole cell controlling bone destruction. Pigment epithelium-derived factor(PEDF) is the strongest anti-angiogenesis factor in human body.Our team found the effect of PEDF to suppress not only angiogenesis but also osteoclast function. PEDF suppressed the osteoclast function supported by chondrosarcoma cell line. Our data suggested that PEDF was the powerful candidate of anti-chondrosarcoma agent.
|
| Free Research Field |
骨軟部腫瘍
|
